INOVA Diagnostics Launches QUANTA Lite Assay for IBD

San Diego, Calif.-based INOVA Diagnostics said Monday it has launched the QUANTA Lite Calprotectin assay for the diagnosis of inflammatory bowel disease.

The FDA-cleared quantitative enzyme-linked immunosorbent assay detects calprotectin levels and can help distinguish IBD from irritable bowel syndrome when used with other laboratory and clinical findings, according to the company.

Detecting accurate calprotectin levels in stool can help doctors determine the appropriate treatment for patients suffering from gastrointestinal disorders, the company says, adding that inaccurate diagnosis at the screening level can contribute to unnecessary procedures and higher healthcare costs.

INOVA Diagnostics is part of the Werfen Group. — Kellen Owings 

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.